Stock MARKSANS MARKSANS PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Marksans Pharma Limited Bombay S.E.

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:49 03/05/2024 BST 		5-day change 1st Jan Change
166.2 INR -0.81% Intraday chart for Marksans Pharma Limited -3.48% +3.33%
04-18 Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA MT
02-14 Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024

Valuation

Fiscal Period: March 2019 2023 2024 2025
Capitalization 1 10,212 31,903 75,203 -
Enterprise Value (EV) 1 10,212 31,903 75,203 75,203
P/E ratio 13.3 x 11 x 22.5 x 18.5 x
Yield - - - -
Capitalization / Revenue 1.02 x - 3.48 x 2.86 x
EV / Revenue 1.02 x - 3.48 x 2.86 x
EV / EBITDA 7.47 x - 14.4 x 11.9 x
EV / FCF - - - -
FCF Yield - - - -
Price to Book - - 3.62 x 3.03 x
Nbr of stocks (in thousands) 409,314 453,164 453,164 -
Reference price 2 24.95 70.40 166.0 166.0
Announcement Date 29/05/19 30/05/23 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2023 2024 2025
Net sales 1 10,001 - 21,583 26,332
EBITDA 1 1,368 - 5,229 6,305
EBIT - - - -
Operating Margin - - - -
Earnings before Tax (EBT) 1 - - 4,490 5,468
Net income 1 804.4 2,653 3,335 4,066
Net margin 8.04% - 15.45% 15.44%
EPS 2 1.870 6.410 7.360 8.970
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 29/05/19 30/05/23 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q3
Net sales 1 5,525
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) 1 1,179
Net income 1 865
Net margin 15.66%
EPS 2 1.910
Dividend per Share -
Announcement Date -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) 15.9% - 16% 16%
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 - - 45.90 54.80
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 29/05/19 30/05/23 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
166
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MARKSANS Stock
  4. MARKSANS Stock
  5. Financials Marksans Pharma Limited